

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
23 March 2023 (23.03.2023)



(10) International Publication Number
WO 2023/044313 A1

(51) International Patent Classification:

C07K 16/24 (2006.01) A61K 39/395 (2006.01)
A61P 17/04 (2006.01)

(21) International Application Number:

PCT/US2022/076387

(22) International Filing Date:

14 September 2022 (14.09.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/244,427 15 September 2021 (15.09.2021) US

(71) Applicant: **DERMIRA, INC.** [US/US]; Lilly Corporate Center, Indianapolis, Indiana 46285 (US).

(72) Inventors: **LIMA, Renata Gontijo**; c/o ELI LILLY AND COMPANY, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **SIU, Kimberly Mung Chee**; c/o ELI LILLY AND COMPANY, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(74) Agent: **GAO, Xiaoguang Michelle et al.**; ELI LILLY AND COMPANY, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,

LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))


Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: IL-13 INHIBITORS FOR THE TREATMENT OF PRURIGO NODULARIS

Figure 1A

IL-13 in PN samples



(57) Abstract: Provided herein are methods and uses of IL-13 inhibitor (e.g., anti-IL-13 antibodies) for treating prurigo nodularis or reducing pruritis associated with prurigo nodularis.

WO 2023/044313 A1